Octreotide is a peptide drug used to treat acromegaly as well as diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide secreting tumors.

Brand Names
Bynfezia, Mycapssa, Sandostatin
Generic Name
DrugBank Accession Number

Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.6 In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.6

Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.8 Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).8 In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.5,7,10

Approved, Investigational
Biologic Classification
Protein Based Therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Not Available
  • Octreotida
  • Octreotide
  • Octreotidum
  • Octrotide
External IDs
  • DRG-0115
  • SMS 201-995
  • SMS-201-995
  • SMS995-AAA



Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors.8 The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.7,13

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAcromegaly•••••••••••••••••••••••••• •• ••• ••••••••• •••••••••••• •••••••• ••••••••••••••••• ••••••• •••••••
Management ofAcromegaly••••••••••••
Treatment ofAcromegaly•••••••••••••••••••• ••••••• •••••••
Treatment ofDiarrhea•••••••••••••••••••••
Symptomatic treatment ofMetastatic carcinoid tumors•••••••••••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Octreotide mimics the naturally occurring hormone known as somatostatin. Like somatostatin, it demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with acromegaly.6,8 In addition, octreotide relieves the flushing and diarrhea associated with gastrointestinal tumors by reducing splanchnic blood flow4 and various gastrointestinal hormones associated with diarrhea.2

Product labeling warns that octreotide may reduce gallbladder contractility, bile secretion, and the release of thyroid-stimulating hormone (TSH) in healthy volunteers.8 In addition, reports of decreased vitamin B12 in patients treated with octreotide have been made. Ensure to monitor vitamin B12 levels in patients taking octreotide.10

Mechanism of action

Octreotide binds to somatostatin receptors coupled to phospholipase C through G proteins and leads to smooth muscle contraction in the blood vessels.9 Downstream effects that stimulate phospholipase C, the production of 1, 4,5-inositol triphosphate, and action on the L-type calcium channels lead to the inhibition of growth hormone, treating the various growth-hormone and metabolic effects of acromegaly.9

Octreotide's suppression of luteinizing hormone (LH)3, reduction in splanchnic blood flow4, and inhibition of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide provide relief for the gastrointestinal and flushing symptoms of carcinoid and/or VIPoma tumors.2

ASomatostatin receptor

After a subcutaneous dose, octreotide is absorbed completely upon administration.2,8 After the administration of an oral delayed-release capsule, peak concentrations were found to be 33% lower than after subcutaneous administration.10 The Cmax was attained at 1.67–2.5 hours after oral administration versus 30 minutes for the subcutaneous route. At 20 mg twice a day in patients with acromegaly, peak concentration was 2.5 mg/nL versus 5.30 ng/mL at 40 mg twice a day.10 AUC increases in proportion with the dose, regardless of the route.2,10

Volume of distribution

In a pharmacokinetic study, the volume of distribution was 13.6 L in healthy volunteers.10 One pharmacokinetic study revealed a volume of distribution ranging from 18.1-30.4L after intravenous administration in healthy volunteers.2

Protein binding

Approximately 65% of the dose is bound in the plasma to lipoproteins and albumin.8,10


Octreotide has been reported to be heavily metabolized in the liver.2

Route of elimination

About 32% of an oral octreotide dose is excreted into the urine 10 and 30-40% is excreted by the liver into the feces.2. About 11% of the unchanged parent drug is found in the urine, and 2% of the unchanged parent drug can be recovered in the feces.2


After a subcutaneous dose, the plasma half-life is estimated to be 0.2 hours. The average elimination half-lives for subcutaneous and oral administration ranged from 2.3 - 2.7 hours and did not differ significantly.10 One pharmacokinetic study revealed a plasma half-life ranging from 72-113 minutes.2


The total body clearance of octreotide is 7-10 L/h.10 One pharmacokinetic study revealed a total body clearance of 11.4 L/h.2

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

There is limited information regarding cases of octreotide overdose aside from case reports of an overdose with injectable octreotide. The dose ranged from 2.4 mg/day to 6 mg/day administered by continuous infusion or subcutaneous administration of 1.5 mg three times daily. Effects of an overdose with octreotide may include hypotension, brain hypoxia, arrhythmia, cardiac arrest, lactic acidosis, pancreatitis, hepatomegaly, diarrhea, flushing, lethargy, and weakness.10

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Octreotide.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Octreotide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.
AcebutololThe serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Acebutolol.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.
Food Interactions
  • Take on an empty stomach. The oral capsules should be taken on an empty stomach. Food reduces oral octreotide absorption by 90%.
  • Take with or without food. Octreotide injections may be taken with or without food.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Octreotide acetate75R0U2568I79517-01-4XQEJFZYLWPSJOV-XJQYZYIXSA-N
International/Other Brands
Sandostatin LAR (Novartis Pharmaceuticals)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BYNFEZIA PenInjection2.5 mg/1mLSubcutaneousSun Pharmaceutical Industries, Inc.2020-04-29Not applicableUS flag
MycapssaCapsule, delayed release20 mg/1OralAmryt Pharmaceuticals Designated Activity Company2020-07-06Not applicableUS flag
MycapssaCapsule, delayed release20 mgOralAmryt Pharmaceuticals DAC2023-02-10Not applicableEU flag
MycapssaCapsule, delayed release20 mg/1OralChiesi USA, Inc.2020-07-06Not applicableUS flag
OcphylSolution500 mcg / mLIntravenous; SubcutaneousPendopharm Division Of Pharmascience Inc2014-05-122018-06-14Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OctreotideInjection, solution500 ug/1mLIntravenous; SubcutaneousFresenius Kabi USA, LLC2006-03-14Not applicableUS flag
OctreotideInjection, solution200 ug/1mLIntravenous; SubcutaneousFresenius Kabi USA, LLC2006-03-14Not applicableUS flag
OctreotideInjection, solution50 ug/1mLIntravenous; SubcutaneousFresenius Kabi USA, LLC2006-03-14Not applicableUS flag
OctreotideInjection, solution100 ug/1mLIntravenous; SubcutaneousFresenius Kabi USA, LLC2006-03-14Not applicableUS flag
OctreotideInjection, solution1000 ug/1mLIntravenous; SubcutaneousFresenius Kabi USA, LLC2006-03-14Not applicableUS flag


ATC Codes
H01CB02 — Octreotide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number


Synthesis Reference

Nishith Chaturvedi, "Novel process for production of the somatostatin analog, octreotide." U.S. Patent US20040225108, issued November 11, 2004.

General References
  1. Biermasz NR: New medical therapies on the horizon: oral octreotide. Pituitary. 2017 Feb;20(1):149-153. doi: 10.1007/s11102-016-0785-3. [Article]
  2. Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002. [Article]
  3. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS: Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet. 1990 Oct 13;336(8720):900-3. doi: 10.1016/0140-6736(90)92270-r. [Article]
  4. Clarke DL, McKune A, Thomson SR: Octreotide lowers gastric mucosal blood flow in normal and portal hypertensive stomachs. Surg Endosc. 2003 Oct;17(10):1570-2. doi: 10.1007/s00464-002-9274-z. Epub 2003 Jul 21. [Article]
  5. Bioworld: Chiasma carries new oral acromegaly treatment, Mycapssa, to FDA approval [Link]
  6. NIH StatPearls: Acromegaly [Link]
  7. FDA approval letter: Mycapssa [Link]
  8. Product monograph: Sandostatin (octreotide acetate) injection [Link]
  9. NIH StatPearls: Octreotide [Link]
  10. FDA Approved Drug Products: Mycapssa (octreotide) delayed-release capsules for oral administration [Link]
  11. Cayman Chem MSDS: Octreotide acetate [Link]
  12. Product monograph: Octreotide injection (octreotide acetate) [Link]
  13. EMA Summary of Product Characteristics: Mycapssa (octreotide) gastro-resistant hard capsules for oral use (December 2022) [Link]
  14. FDA Approved Drug Products: Sandostatin (octreotide acetate) for subcutaneous or intravenous injection [Link]
KEGG Compound
PubChem Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page
Drugs.com Drug Page
FDA label
Download (69.7 KB)

Clinical Trials

Clinical Trials
4CompletedNot AvailablePituitary Adenoma1
4CompletedPreventionDiarrhea / Neoplasm1
4CompletedSupportive CareColonic Motility Index / Constipation1
4CompletedTreatmentAscites / Cirrhosis of the Liver1


  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva parenteral medicines inc
  • Novartis pharmaceuticals corp
  • APP Pharmaceuticals
  • Bachem Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Novartis AG
  • Polfa
  • Sandoz
  • Sicor Pharmaceuticals
  • Solvay Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Dosage Forms
InjectionSubcutaneous2.5 mg/1mL
SolutionParenteral1 mg
SolutionParenteral1.000 mg
Injection, powder, for suspensionParenteral10 MG/2ML
Injection, powder, for suspensionParenteral10 MG
Injection, powder, for suspensionParenteral20 MG/2ML
Injection, powder, for suspensionParenteral20 MG
Injection, powder, for suspensionParenteral30 MG/2ML
Injection, powder, for suspensionParenteral30 MG
Injection, solution100 MICROGRAMMI/ML
Injection, solution100 MICROGRAMMI/1ML
Injection, solution1000 MICROGRAMMI/5ML
Injection, solution50 MICROGRAMMI/ML
Injection, solution50 MICROGRAMMI/1ML
Injection, solution500 MICROGRAMMI/ML
Injection, solution500 MICROGRAMMI/1ML
Capsule, delayed releaseOral20 mg
Capsule, delayed releaseOral20 mg/1
Injection0.1 mg
InjectionIntravenous1000 ug/1mL
InjectionIntravenous200 ug/1mL
InjectionIntravenous; Subcutaneous100 ug/1mL
InjectionIntravenous; Subcutaneous1000 ug/1mL
InjectionIntravenous; Subcutaneous200 ug/1mL
InjectionIntravenous; Subcutaneous50 ug/1mL
InjectionIntravenous; Subcutaneous500 ug/1mL
Injection, solutionIntravenous200 ug/1mL
Injection, solutionIntravenous; Subcutaneous100 ug/1mL
Injection, solutionIntravenous; Subcutaneous1000 ug/1mL
Injection, solutionIntravenous; Subcutaneous200 ug/1mL
Injection, solutionIntravenous; Subcutaneous50 ug/1mL
Injection, solutionIntravenous; Subcutaneous500 ug/1mL
PowderNot applicable1 g/1g
SolutionIntravenous; Subcutaneous100 mcg / mL
SolutionIntravenous; Subcutaneous50 mcg / mL
SolutionIntravenous; Subcutaneous500 mcg / mL
Injection, solutionParenteral0.05 MG/ML
Injection, solutionParenteral0.1 MG/ML
Injection, solutionParenteral0.5 MG/ML
Injection, solutionParenteral1 MG/5ML
Injection, powder, for suspension, extended release; kitIntramuscular10 mg / vial
Injection, powder, for suspension, extended release; kitIntramuscular20 mg / vial
Injection, powder, for suspension, extended release; kitIntramuscular30 mg / vial
Injection, solutionParenteral0.2 MG/ML
Injection, solutionParenteral0.05 MG/1ML
Injection, solutionParenteral0.1 MG/1ML
Injection, solutionParenteral0.5 MG/1ML
Injection, powder, for suspension, extended releaseIntramuscular10 MG/vial
Injection, powder, for suspension, extended releaseIntramuscular20 MG/vial
Injection, powder, for suspension, extended releaseIntramuscular30 MG/vial
Injection, powder, for suspension
Injection, solution
InjectionIntravenous; Subcutaneous
SolutionIntravenous; Subcutaneous200 mcg / mL
Solution0.1 mg/1ml
Solution0.5 mg/1ml
Injection, solution0.1 mg/ml
Injection, solutionParenteral100 Mikrogramm/ml
Injection, solutionParenteral
Injection, solutionParenteral50 Mikrogramm/ml
Injection, solutionParenteral500 Mikrogramm/ml
SolutionParenteral0.05 mg
SolutionParenteral0.1 mg
InjectionSubcutaneous0.05 mg/ml
InjectionSubcutaneous0.1 mg/ml
Injection, powder, for solutionIntramuscular10 mg
Injection, powder, for solutionIntramuscular20 mg
Injection, powder, for solutionIntramuscular30 mg
Injection, powder, for suspension, extended releaseIntramuscular10 mg / vial
Injection, powder, for suspension, extended releaseIntramuscular20 mg / vial
Injection, powder, for suspension, extended releaseIntramuscular30 mg / vial
Powder10 mg/1vial
Injection, suspension10 mg
Injection, suspension20 mg
Powder20 mg/1vial
Powder30 mg/1vial
Injection, suspension30 mg
Injection, powder, for suspension; kitIntramuscular1.667 mg/1mL
Injection, powder, for suspension; kitIntramuscular3.33 mg/1mL
Injection, powder, for suspension; kitIntramuscular5 mg/1mL
KitIntramuscular1.667 mg/1mL
KitIntramuscular10 mg/1
KitIntramuscular20 mg/1
KitIntramuscular3.33 mg/1mL
KitIntramuscular30 mg/1
KitIntramuscular5 mg/1mL
InjectionIntramuscular10 mg
InjectionIntramuscular20 mg
InjectionIntramuscular30 mg
InjectionParenteral0.2 mg
SolutionIntravenous; Subcutaneous0.1 mg
Injection, powder, for suspensionIntramuscular30 mg
Injection, powder, for suspensionIntramuscular20 mg
Injection, solution1 MG/5ML
Injection, solutionParenteral100 μg/ml
Injection, solutionParenteral500 μg/ml
SolutionParenteral0.200 mg
SuspensionParenteral20.000 mg
Injection, powder, lyophilized, for solutionIntravenous; Subcutaneous200 cg
Injection, solutionParenteral200 MICROGRAMMI/ML
Injection, solutionParenteral100 MICROGRAMMI/ML
Injection, solutionParenteral500 MICROGRAMMI/ML
Injection, solution0.1 mg/1ml
Unit descriptionCostUnit
Sandostatin lar 30 mg kit3860.62USD kit
Sandostatin lar 20 mg kit2578.19USD kit
Sandostatin lar 10 mg kit1967.81USD kit
Sandostatin 1 mg/ml vial234.49USD ml
Sandostatin 0.5 mg/ml ampul111.48USD ml
Octreotide 1000 mcg/ml vial67.2USD ml
Sandostatin 0.2 mg/ml vial47.66USD ml
Octreotide acet 500 mcg/ml vial24.48USD ml
Sandostatin 0.1 mg/ml ampul23.11USD ml
Octreotide acet 100 mcg/ml vial15.36USD ml
Octreotide acet 200 mcg/ml vial14.4USD ml
Sandostatin 0.05 mg/ml ampul11.92USD ml
Octreotide acet 50 mcg/ml vial3.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5538739No1996-07-232013-07-23US flag
CA1328402No1994-04-122011-04-12Canada flag
US5922338Yes1999-07-132017-01-13US flag
US5922682Yes1999-07-132017-01-13US flag
US5728396No1998-03-172017-01-30US flag
US6156331No2000-12-052017-01-30US flag
US6375978No2002-04-232018-12-17US flag
US6235712No2001-05-222017-06-13US flag
US6113938No2000-09-052018-07-24US flag
US6124261No2000-09-262017-06-13US flag
US6395292No2002-05-282017-01-30US flag
US6132420No2000-10-172017-01-30US flag
US5985305No1999-11-162017-01-30US flag
US5932547No1999-08-032017-06-13US flag
US5753618Yes1998-05-192015-11-19US flag
US10342850No2019-07-092038-05-15US flag
US10695397No2020-06-302036-02-03US flag
US8535695No2013-09-172029-09-17US flag
US10238709No2019-03-262036-02-03US flag
US9566246No2017-02-142029-09-17US flag
US8329198No2012-12-112029-09-17US flag
US9265812No2016-02-232029-09-17US flag
US11052126No2021-07-062036-02-03US flag
US11141457No2021-10-122040-12-28US flag
US11338011No2016-02-032036-02-03US flag
US11510963No2016-02-032036-02-03US flag


Experimental Properties
melting point (°C)153-156https://www.chemicalbook.com/ChemicalProductProperty_US_CB0279552.aspx
boiling point (°C)1447https://www.chemenu.com/products/CM100710


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
1. Somatostatin receptor
Pharmacological action
This group is comprised of various subtypes of somatostatin receptors.
  1. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD: Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary. 2009;12(4):297-303. doi: 10.1007/s11102-009-0175-1. [Article]
  2. Mulak A, Larauche M, Biraud M, Million M, Rivier J, Tache Y: Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice. Peptides. 2015 Jan;63:71-80. doi: 10.1016/j.peptides.2014.10.013. Epub 2014 Nov 5. [Article]
  3. Product monograph: Sandostatin (octreotide acetate) injection [Link]
  4. NIH StatPearls: Octreotide [Link]


Pharmacological action
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
83867.71 Da
  1. Alatas E, Alatas O, Colak O: Octreotide inhibits myeloperoxidase activity in rat uterus. Acta Obstet Gynecol Scand. 2000 Jul;79(7):524-7. [Article]
  2. Alatas E, Gunal O, Alatas O, Colak O: Octreotide prevents postoperative adhesion formation by suppressing peritoneal myeloperoxidase activity. Hepatogastroenterology. 2000 Jul-Aug;47(34):1034-6. [Article]
Pharmacological action
Curator comments
This enzyme action is based on limited findings of in vitro studies and the clinical relevance is unknown.
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
  1. Yilmaz B, Kemal Y, Teker F: Be careful before prescribing warfarin and octreotide together: a new drug-drug interaction report. Hippokratia. 2014 Oct-Dec;18(4):377. [Article]
  2. Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC: Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab. 1998 Jul;83(7):2411-6. [Article]


Pharmacological action
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
Uniprot ID
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
  1. Product monograph: Sandostatin (octreotide acetate) injection [Link]


Pharmacological action
Curator comments
P-glycoprotein is a possible transporter of octreotide, according to the findings of various in vitro studies.
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
Uniprot ID
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
  1. Gutmann H, Miller DS, Droulle A, Drewe J, Fahr A, Fricker G: P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6. doi: 10.1038/sj.bjp.0703003. [Article]
  2. Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y: Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. Biol Pharm Bull. 1998 Aug;21(8):874-8. doi: 10.1248/bpb.21.874. [Article]
  3. Dietrich CG, Geier A, Oude Elferink RP: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 2003 Dec;52(12):1788-95. doi: 10.1136/gut.52.12.1788. [Article]
Pharmacological action
Curator comments
Octreotide is a substrate and weak inhibitor of MRP2, according to various in vitro studies.
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
Uniprot ID
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
  1. Gutmann H, Miller DS, Droulle A, Drewe J, Fahr A, Fricker G: P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6. doi: 10.1038/sj.bjp.0703003. [Article]
  2. Visentin M, Stieger B, Merz M, Kullak-Ublick GA: Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2. J Pharmacol Exp Ther. 2015 Nov;355(2):145-51. doi: 10.1124/jpet.115.227546. Epub 2015 Sep 1. [Article]
  3. Dietrich CG, Geier A, Oude Elferink RP: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 2003 Dec;52(12):1788-95. doi: 10.1136/gut.52.12.1788. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 03, 2024 02:17